Ex­clu­sive: On­col­o­gy start­up from Sanger In­sti­tute nabs $28M, ex-No­var­tis SVP as CEO

The Well­come Sanger In­sti­tute’s lat­est on­col­o­gy spin­out will en­ter the clin­ic in about 18 to 24 months with a new CEO at the helm and $28 mil­lion in Se­ries A funds.

Called Mo­sa­ic Ther­a­peu­tics, the start­up is work­ing on new tar­get­ed treat­ments from the labs of Sanger’s Math­ew Gar­nett and Sanofi board mem­ber Emile Voest, who works at the Nether­lands Can­cer In­sti­tute and On­code In­sti­tute. Al­so on the co-found­ing team is for­mer Sanger head of tech­nol­o­gy trans­la­tion Adri­an Ibrahim.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER